Delavirdine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | RESCRIPTOR | — | 2001-05-16 | fda.gov ↗ |
| Approved | US (FDA) | RESCRIPTOR | — | 1997-04-04 | fda.gov ↗ |
Trials 19
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delavirdine | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ |
| Known as | Delavirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL593 ↗ |
| Known as | Delavirdine mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL593 ↗ |
| Known as | Delavirdine mesylate | “The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to...” NCT00002210 ↗3“Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)” NCT00000810 ↗ “Delavirdine mesylate ( U-90152 )” NCT00000803 ↗ |
| Known as | Delavirdine methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL593 ↗ |
| Known as | DLV | “An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens...” NCT00002211 ↗11“Zidovudine (ZDV), lamivudine (3TC), stavudine (d4T), didanosine (ddI), delavirdine (DLV), ritonavir (RTV), and saquinavir soft gel capsules (SQV sgc) are provided on-study.” NCT00000891 ↗ “The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients.” NCT00002401 ↗ “Arm A: Saquinavir (SQV) plus ritonavir (RTV) plus delavirdine (DLV) plus adefovir dipivoxil placebo.” NCT00000892 ↗ “delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV)” NCT00002236 ↗ “Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)” NCT00000810 ↗ “delavirdine mesylate (DLV)” NCT00002124 ↗ “delavirdine (DLV)” NCT00001094 ↗ “Delavirdine (DLV)” NCT00000882 ↗ “delavirdine (DLV)” NCT00002420 ↗ “delavirdine (DLV)” NCT03631732 ↗ |
| Known as | Rescriptor | “An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens...” NCT00002211 ↗3“The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to...” NCT00002210 ↗ “An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) in Triple and Quadruple Combinations With Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in...” NCT00002401 ↗ “Rescriptor (Delavirdine Mesylate)” NCT00002420 ↗ |
| Known as | U-90152 | “To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 ) after multiple doses given orally to asymptomatic HIV-1 positive patients who are...” NCT00002312 ↗2“delavirdine mesylate ( U-90152 ) monotherapy” NCT00000810 ↗ “Delavirdine mesylate ( U-90152 )” NCT00000803 ↗ |
| Known as | U-90152S | “Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)” NCT00000810 ↗ |
| Known as | U-90152T | ChEMBL registry synonym — accepted as the source's own label CHEMBL593 ↗ |
| Action | Inhibit | “nonnucleoside reverse transcriptase inhibitor (NNRTI) DLV” NCT00000882 ↗ |
| Modality | Small molecule | “bisheteroarylpiperazines (BHAPs) such as delavirdine mesylate are potent and safe anti-HIV agents” NCT00000810 ↗ |
| Route | Oral | “multiple doses given orally” NCT00002312 ↗ |